Jiangsu Recbio Technology Co., Ltd.

Research Jiangsu Recbio Technology Co., Ltd. (G93) on Bullrun: market cap EUR 344.34M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerG93
ExchangeF
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyEUR
Market capEUR 344.34M
Financial periodFY2025
RevenueCNY 12.73M
Net income-CNY 610.39M
Free cash flow-CNY 601.50M
Gross margin88.3%

Valuation Snapshot

latest market cap is EUR 344.34M.

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 12.73M	-CNY 610.39M	-CNY 601.50M	88.3%	n/a	CNY 351.84M	CNY 638.47M	CNY 705.84M
FY2024	CNY 0	-CNY 562.39M	-CNY 636.66M	n/a	-1.16	CNY 319.04M	CNY 889.10M	CNY 529.32M
FY2023	CNY 0	-CNY 571.96M	-CNY 862.18M	n/a	-1.19	CNY 834.98M	CNY 650.80M	CNY 1.07B
FY2022	CNY 0	-CNY 722.70M	-CNY 888.04M	n/a	-1.52	CNY 1.33B	CNY 282.63M	CNY 1.66B
FY2021	CNY 0	-CNY 657.56M	-CNY 710.79M	n/a	-1.47	CNY 1.18B	CNY 76.72M	CNY 1.67B

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-08-15	EUR 344.34M	n/a	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About Jiangsu Recbio Technology Co., Ltd.

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company develops vaccines for the treatment of cervical cancers, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601, a recombinant HPV bivalent vaccines targeting HPV type 16/18 that is in phase I clinical trial;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

WUXI BIOLOGICS-00000083 (1FW2) ZAI LAB LTD0000006 (1ZLB) Ascletis Pharma Inc (2VJ) ALPHAMAB ONCOLO.DL-000002 (3NK) AKESO INC. O.N. (4RY) Duality Biotherapeutics, Inc. (4ZB) OCUMENSION THER.DL-00001 (5DG) Shanghai Haohai Biological Technology Co. Ltd (5HB) KEYMED BIOSCIENCES -0001 (64Z) EVEREST MED.LTD DL-0001 (6HN) Innovent Biologics Inc (6IB) HBM HLDGS LTD DL-000025 (6XY)

Frequently asked questions

What is Jiangsu Recbio Technology Co., Ltd.'s market cap?

Jiangsu Recbio Technology Co., Ltd.'s market capitalization is EUR 344.34M.

What does Jiangsu Recbio Technology Co., Ltd. do?

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China.